An investigative media outlet\u0026#039;s probe of closed-door negotiations between European officials and pharmaceutical companies indicates that ensuring equitable, universal access to coronavirus vaccines worldwide was never a top priority of the talks, despite political leaders\u0026#039; repeated claims to the contrary.\r\n\r\nAfter speaking with current and former negotiators, United Nations representatives, NGO officials, and politicians, Investigate Europe reported Thursday that \u0022access for all was never a priority\u0022 in initial vaccine procurement talks, which set the stage for the present inoculation gap between rich and poor countries. Of the more than 6 billion coronavirus vaccine doses that have been administered globally to date, just 2.2% have gone to people in low-income nations.\r\n\r\n\u0022The words \u0026#039;global public goods\u0026#039; are an empty shell,\u0022 said one unnamed negotiator, referring to a phrase that some of Europe\u0026#039;s top political leaders—including French President Emmanuel Macron and German Chancellor Angela Merkel—used in the early stages of the pandemic to characterize their approach to vaccine production and distribution.\r\n\r\nAnother negotiator told the outlet that \u0022there was strong nationalism on the European level,\u0022 a stance that has fueled major European countries\u0026#039; opposition to a proposed patent waiver for Covid-19 vaccines. Pharmaceutical companies in Europe have lobbied aggressively against the patent waiver, which would endanger the drug industry\u0026#039;s monopoly control over vaccine production.\r\n\r\nInstead of supporting a temporary suspension of patent protections, European Union leaders have\u0026nbsp;provided funding to COVAX and pledged to donate hundreds of millions of excess doses to low-income countries—efforts that have not yet made much of a dent in global vaccine inequities.\r\n\r\nThe People\u0026#039;s Vaccine Alliance, a global coalition of more than 70 humanitarian and public health organizations, tweeted Thursday that Investigate Europe\u0026#039;s story \u0022details what we suspected all along.\u0022\r\n\r\n\u0022Vaccine nationalism and pharma profits trumped Covid solidarity,\u0022 the coalition wrote.\r\n\r\nInvestigate Europe found over the course of its probe that secretive negotiations between largely anonymous European negotiators and vaccine makers allowed \u0022Pfizer/Biontech and Moderna to increase the bill for European taxpayers\u0022 and ensure that any effort to treat vaccines as a global public good was \u0022shelved\u0022 early on.\r\n\r\n\u0022What\u0026#039;s more, deals have long remained secret, despite €3 billion of so-called Advanced Purchase Agreements to secure orders and de-risk production for drugmakers,\u0022 the outlet reported, noting that contract-related documents that have been released thus far have been so heavily redacted as to be meaningless.\r\n\r\n\r\n\r\nModerna, Pfizer, and the latter\u0026#039;s German partner BioNTech \u0022have reaped over $60 billion in jab sales in 2021 and 2022,\u0022 Investigate Europe observed. The pharmaceutical giants have sold much of their vaccine supply to rich countries; Moderna hasn\u0026#039;t delivered a single vaccine dose to a low-income nation thus far, according to an Amnesty International report published earlier this week.\r\n\r\n\u0022Documents seen by the Financial Times revealed that Pfizer\u0026#039;s vaccine now fetches €19.50 against €15.50 previously,\u0022 the outlet noted. \u0022Similarly, a dose of Moderna costs $25.50 (€21.60), up from $22.50 in the first deal, although down from $28.50 in the second.\u0022\r\n\r\nSuch price hikes came despite a September 2020 promise from the E.U. Commission\u0026#039;s top vaccine negotiator,\u0026nbsp;Sandra Gallina, that vaccine doses would cost European governments between €5 and €15.\r\n\r\n\r\n\r\nNegotiators claimed in interviews with Investigate Europe that \u0022their hands were tied\u0022 in price talks with pharmaceutical companies because of the \u0022lucrative contracts already signed by the United States.\u0022\r\n\r\n\u0022[Former U.S. President Donald] Trump set up a market based on secrecy and high prices,\u0022 said one of the negotiators. Another said that \u0022Big Pharma are very good at pressuring.\u0022\r\n\r\n\u0022If you don\u0026#039;t sign their contracts,\u0022 the unnamed negotiator said, \u0022others will do.\u0022\r\n\r\nAnna Marriott, policy lead for the People\u0026#039;s Vaccine Alliance, told Investigate Europe that \u0022vaccine corporations have been greedy,\u0022 effectively getting taxpayers to pay for vaccines three times over.\r\n\r\n\u0022First with billions for research, then with bloated prices draining public funds, and finally because they\u0026#039;re paying little in taxes,\u0022 said Marriott.